ANIK Q4 2019 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$208M

Q4 2019 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$30M+10.4% YoY

Gross Profit

$21M70.9% margin

Operating Income

$5M16.1% margin

Net Income

$4M13.6% margin

EPS (Diluted)

$0.28

QoQ Revenue Growth

+0.3%

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$331M

Total Liabilities

$42M

Stockholders' Equity

$288M

Cash & Equivalents

$157M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$27M	+10.4%
Gross Profit	$21M	$20M	+5.9%
Operating Income	$5M	$10M	-50.8%
Net Income	$4M	$8M	-47.5%

Revenue Segments

Product

$30M50%

Orthobiologics

$26M44%

Manufactured Product, Other

$1M2%

Dermal

$1M2%

Surgical

$1M2%

Geographic Segments

UNITED STATES

$24M88%

Europe

$3M12%